New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
Khalid El BairiAinhoa MadariagaDario TrapaniOuissam Al JarroudiSaid AfqirPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Platinum-resistant ovarian cancer is difficult to treat and has a poor prognosis. Patients with platinum-resistant ovarian cancer have limited treatment options and often have a limited benefit from existing chemotherapeutic agents. There is a lack of contemporary effective anticancer drugs and reliable predictive biomarkers for this aggressive cancer. Recent cutting-edge research presented at the 2023 American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) Annual Meetings has provided insights into several potential therapeutic targets, such as DNA damage repair proteins, cell-cycle regulators, and immune-modulating agents. In addition, antibody-drug conjugates have provided new practice-changing results in platinum-resistant ovarian cancer. Here, we review the results of research presented at this annual event, with a focus on clinical trials investigating novel treatment approaches for platinum-resistant ovarian cancer, in addition to predictive and prognostic biomarkers for optimal patient selection, and other topics, such as real-world evidence.
Keyphrases
- poor prognosis
- cell cycle
- palliative care
- dna damage
- clinical trial
- healthcare
- long non coding rna
- cell proliferation
- primary care
- oxidative stress
- randomized controlled trial
- papillary thyroid
- signaling pathway
- transcription factor
- drug delivery
- dna repair
- risk assessment
- young adults
- cancer therapy
- smoking cessation